Production of therapeutic proteins in genetically modified mammalian cells

US10030063B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Mara Fornaro · Basel, CH
• David Glass · Cambridge, US
• Thomas Jostock · Neuenburg am Rhein, DE
• Holger Laux · Irslingen, DE
• Sandrine Romand · Seyssinet-Pariset, FR

Key dates

• Filing date: Dec 16, 2013
• Grant date: Jul 24, 2018
• Expiry date: Mar 14, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2310/531
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

The invention relates to methods for the production of therapeutic proteins in mammalian cells. In one embodiment, the method comprises producing a therapeutic protein such as IGF-1 in a mammalian cell endogenously expressing a cognate receptor of said recombinant therapeutic protein and wherein binding of said therapeutic protein to said cognate receptor results in a low titer of the therapeutic protein, the method comprising with a mammalian cell being deficient in the expression of the cognate receptor of said therapeutic protein and being transformed with an expression vector comprising a nucleic acid molecule encoding the therapeutic protein: a. Cultivating said cell under conditions allowing the expression of the therapeutic protein; and b. Harvesting the therapeutic protein from the mammalian cell cultivated in step a, wherein said mammalian cell produces at least 1.5 fold more therapeutic protein than a cell in which the expression of the cognate receptor has not been so modified.